SCHEMBL4737864

SCHEMBL4737864

O=c1cc(O)nc(-c2cccc(Br)c2)n1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.53
MAPT P10636 6/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HTT P42858 1/20 0.46
BCL2 P10415 1/20 0.46
MCL1 Q07820 1/20 0.46
ALDH1A1 P00352 6/20 0.45
CYP1A2 P05177 1/20 0.45
GAA P10253 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 2/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737051 0.88 BCL2 (0.55) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4995678 0.84 SMN1; SMN2 (0.51) LMNASMN1; SMN2KMT2ABCL2MCL1
SCHEMBL4737515 0.80 CASR (0.45) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4741283 0.78 CFD (0.52) MAPTTP53HDAC8HDAC6
SCHEMBL4784822 0.78 MEN1 (0.45) MAPTSMN1; SMN2MEN1KMT2ABCL2
SCHEMBL5000326 0.77 CCR9 (0.47) LMNASMN1; SMN2MEN1KMT2AHTT
SCHEMBL5000196 0.77 ALDH1A1 (0.59) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4741826 0.77 CCR2 (0.43) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL3521617 0.76 ALDH1A1 (0.51) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL4740165 0.75 KDM4E (0.48) MAPTLMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 CFTR 3703/4885MAPT 4781/4885LMNA 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.